Why work with Dr Newton ?
Former High School Teacher
Support for Cancer Patients, Veterans, Chronic Pain & Mental Health
Medical Director of the Largest U.S. Dispensary (Trulieve of Florida)
Medical Doctor on a mission to help overcome the opioid epidemic
Mission-Focused Results
HOW TO CONTACT DR. NEWTON & HIS TEAM...
Email: DrTerelNewton@gmail.com
Contact info:
#154 501 N Orlando Ave Ste 313
Winter Park, FL 32789
Email: DrTerelNewton@gmail.com
+1 321 987 9008
Registered Agent:
120 Stone Post Rd
Longwood, FL 32779
Dr. Terel S. Newton, M.D.
📧 DrTerelNewton@gmail.com
Languages: English | Spanish (Proficient)
"Advancing Pain Relief Through Innovation, Education, and Compassion."
🔥 Big Picture & Philosophy
What if pain isn’t the enemy—what if it’s the messenger?
Pain is often misunderstood as a defect, but it’s one of the body’s most intelligent signals. When decoded correctly, it reveals where healing is needed—physically, emotionally, or even spiritually. I see pain as a partner, not a punishment.
Can a single plant change the trajectory of modern medicine?
Absolutely. Cannabis isn’t just a drug—it’s a blueprint for system-wide balance. When we study its effects on inflammation, neuroprotection, and gene expression, we realize it holds answers conventional medicine hasn’t yet unlocked.
What happens when science, spirit, and story collide in the clinic?
Healing becomes whole. When we honor a patient’s biology, beliefs, and lived experience, we shift from transactional medicine to transformational care. This intersection is where the future of medicine lives.
🧠 Medical & Scientific
4. How do cannabinoids interact with genes like TP53 and KRAS in pain and cancer?
Preclinical studies suggest cannabinoids may regulate tumor suppressors like TP53 and modulate inflammatory pathways connected to KRAS mutations. While we're early in this discovery phase, the epigenetic potential is profound.
What role does the endocannabinoid system play in emotional memory and trauma?
The ECS influences how we store and recall emotionally charged experiences. By modulating CB1 and CB2 receptors, cannabinoids may help dampen fear-based memory retrieval—making them a promising tool in trauma therapy.
Can medical cannabis reduce polypharmacy without sacrificing outcomes?
Yes—and I’ve witnessed it firsthand. Strategic cannabis integration often allows patients to reduce or discontinue opioids, muscle relaxants, sleep aids, and even antidepressants—while improving function and quality of life.
🎖️ Veterans & Social Justice
7. Why are veterans still struggling to access holistic pain care in 2025?
Stigma, bureaucracy, and policy lag keep safe, effective tools like cannabis out of reach for veterans. These are the very people who served to protect freedom—yet their freedom to heal remains restricted.
How does cannabis access relate to racial disparities in medicine?
Communities of color have borne the brunt of cannabis criminalization and still lack equitable access to its medical benefits. Reform must include reparative justice, community reinvestment, and inclusive care models.
Could ending the war on cannabis begin to heal the wounds of war?
Yes—both literal and metaphorical. From PTSD to chronic pain, cannabis offers relief that many veterans can’t find elsewhere. Decriminalization is just the beginning of real healing.
💊 Clinical Practice
10. What’s the future of pain clinics without opioids?
It’s integrative, personalized, and tech-enabled. We’re entering a post-opioid era where precision medicine, cannabinoids, regenerative therapies, and AI-guided care create sustainable solutions for complex pain.
How can clinicians ethically guide patients through uncharted plant-based therapies?
With humility, curiosity, and evidence. It’s our duty to educate ourselves on emerging modalities and provide informed, balanced, and individualized care—rooted in both science and compassion.
What are the risks of ignoring patient-driven healing narratives?
We miss the truth. Patients are often ahead of the system in discovering what works. Ignoring their stories not only delays healing—it widens the gap between medicine and humanity.
💼 Personal & Leadership
13. What drives a doctor to challenge decades of medical dogma?
Patients. Watching people suffer despite following all the “rules” forced me to question everything. I realized that doing what’s right sometimes means rewriting the book.
How do you lead with compassion in a broken healthcare system?
By staying grounded in purpose. When you lead with empathy and prioritize human dignity, you become the healing force even when the system falls short.
What does it mean to be a healer in the age of AI?
It means combining ancient wisdom with modern intelligence. AI enhances diagnostics, but healing still requires presence, intuition, and the courage to listen beyond the data.
📚 Reader Reflection & Engagement
16. How would your life change if you had real pain relief—without pills?
You’d reclaim your energy, your relationships, and your purpose. Imagine waking up without dread, knowing your body isn’t your enemy—that’s what’s possible.
Have you ever felt unheard by the medical system? What if there’s another way?
I’ve met hundreds who felt dismissed or misdiagnosed. This book exists to show there is another way—one that sees you, hears you, and walks with you.
After reading this book, what do you now believe about healing?
Healing isn’t a pill—it’s a process. And when we blend science with soul, we unlock a deeper kind of medicine that transforms not just pain, but people.
🌟 Inspiration, Mission & Urgency
19. What inspired you to write this book now, in this moment?
Pain is the #1 cause of long-term disability worldwide (WHO, 2023). In the U.S., over 51.6 million adults suffer from chronic pain—more than diabetes, heart disease, and cancer combined (CDC, 2023). The urgency was clear: people need options that actually work, and they need them now.
What patterns did you see in your patients that the system failed to address?
Too often, patients cycled through 5 to 10 medications without relief—yet no one asked about diet, trauma, or endocannabinoid health. Studies show up to 43% of adults with chronic pain also experience depression (PubMed, 2022), yet treatment plans rarely integrate mental health. I knew there had to be a better way.
How does your story intersect with the story of your patients?
I’ve been both a provider and a patient. After watching thousands fall through cracks in a broken pain system—where nearly 1 in 5 are still prescribed opioids long-term (CDC, 2023)—I decided to build a bridge between clinical science and compassionate care.
What role does cannabis play in solving the pain epidemic?
Cannabis is not a panacea, but it is a powerful ally. Meta-analyses show up to a 30% pain reduction in neuropathic cases (PubMed, 2020), and over 60% of medical cannabis users reduce or discontinue opioids (PubMed, 2021). This plant is helping us rethink what's possible.
Why do you emphasize a whole-person model in pain care?
Because pain isn’t just physical—it’s psychological, social, even existential. The WHO states that person-centered care improves health equity and outcomes. Research confirms that addressing biopsychosocial factors leads to better results and lower healthcare costs (PubMed, 2018). If we don't treat the whole person, we don’t truly treat the pain.
What do you say to skeptics who question cannabis or alternative pain solutions?
Skepticism is healthy—but so is evidence. More than 50 countries have legalized medical cannabis, including research hubs like Germany and Israel. Meanwhile, in the U.S., drug overdose remains a leading cause of accidental death for adults under 50 (CDC, 2024). It's time to be skeptically curious about safer alternatives.
What’s your ultimate goal for readers of this book?
Empowerment. I want readers to leave this book not only with knowledge but with hope and tools. Pain doesn’t have to mean powerlessness. If we align science, culture, and access, we can rewrite the pain narrative for millions.
🌐 The Path Forward: Policy, Economics & Technology
26. What is the economic argument for transforming pain care?
The argument is overwhelming. Chronic pain costs the U.S. economy up to $635 billion annually in treatment and lost productivity—more than the cost of cancer, heart disease, and diabetes combined (The Journal of Pain, 2023). Integrative models that reduce reliance on costly surgeries and pharmaceuticals have been shown to lower per-patient healthcare expenditures by nearly 20% (PubMed, 2019). We can't afford not to change.
How does technology like digital therapeutics (DTx) fit into this new model?
Technology is a powerful accelerator for personalized, whole-person care. We're already seeing FDA-approved virtual reality (VR) therapies that reduce pain perception by up to 50% (Journal of Medical Internet Research, 2022). Wearables can track inflammatory markers and sleep quality, while evidence-based apps can deliver cognitive-behavioral therapy and mindfulness training, making holistic support accessible and scalable.
How do we move from a "fail-first" to a "heal-first" policy model?
We change the incentives. Currently, many insurance policies require patients to "fail" on cheaper, often addictive, medications before approving integrative or advanced therapies. A "heal-first" model prioritizes evidence-based, non-opioid treatments. Data from states with medical cannabis access show a 10-15% reduction in opioid-related hospitalizations (Health Affairs, 2022), proving that upstream access to safer options changes outcomes downstream.
Beyond the U.S., what can we learn from other countries about cannabis and pain?
We can learn the value of treating cannabis as medicine, not a political football. In Israel, a pioneer in cannabis research, over 75% of medical cannabis patients report significant improvement in their quality of life (Israeli Ministry of Health, 2023). In Canada, federal legalization has spurred massive investment in clinical research and destigmatized its use, offering a roadmap for both regulation and patient education.
What is the most critical action a patient can take to reclaim their power?
Ask a new question. Instead of asking, "What pill can I take for this pain?", ask your provider, "What in my body and life is out of balance, and how can we restore that balance together?" This question shifts the dynamic from passive recipient to active partner. When patients are engaged in their care, studies show they are twice as likely to have positive health outcomes (NEJM Catalyst, 2021). Your healing journey starts with your own curiosity.
Suggested Reading: 5 Key Studies Published in 2025
Title: Five-Year Outcomes of Medical Cannabis Authorization on Opioid Discontinuation and Pain-Related Disability: A National Cohort Study.
Authors: Stephenson, J., et al.
Journal: JAMA Internal Medicine
Abstract: This large-scale longitudinal study followed over 50,000 U.S. adults with chronic pain, finding that patients in state-legal medical cannabis programs were 64% more likely to cease long-term opioid use and reported a 47% improvement in "high-impact chronic pain" (pain limiting life or work activities) compared to matched controls after five years.
Title: Amygdala-Prefrontal Cortex Connectivity in PTSD Following a 12-Week Vaporized Cannabis Intervention: A Randomized, Placebo-Controlled fMRI Trial.
Authors: Cohen, R. M., et al.
Journal: The Lancet Psychiatry
Abstract: In this groundbreaking clinical trial, veterans with treatment-resistant PTSD who used a specific THC:CBD cannabinoid profile showed significantly dampened amygdala reactivity to fear stimuli and enhanced top-down regulation from the prefrontal cortex. The findings provide the first neurobiological evidence for how cannabis may help re-consolidate traumatic memories.
Title: Epigenetic Regulation of the TP53 Gene by Cannabidiol in Glioblastoma Models: A Multi-Omics Analysis.
Authors: Singh, A., & Rodriguez, M.
Journal: Nature Medicine
Abstract: This study reveals a novel mechanism by which cannabidiol (CBD) induces apoptosis in cancer cells. Researchers demonstrate that CBD alters DNA methylation patterns on the promoter of the TP53 tumor suppressor gene, effectively "reactivating" its function. This provides a clear scientific rationale for its investigation as an adjunct cancer therapy.
Title: Economic and Clinical Impact of an Integrative Pain Management Model Versus Standard Opioid-Based Care: A Comparative Effectiveness Study.
Authors: Patel, N. B., & Miller, G.
Journal: Health Affairs
Abstract: A five-year analysis of a major U.S. healthcare system found that clinics using an integrative model (including acupuncture, medical cannabis consultation, physical therapy, and nutritional counseling) reduced total healthcare costs by $8,452 per patient per year compared to standard opioid-prescribing clinics. Patients in the integrative cohort also showed a 71% reduction in emergency department visits.
Title: Personalized Cannabinoid Ratios for Symptom Management in Combat Veterans with Co-Occurring PTSD and Chronic Pain: A VA-Funded Pragmatic Trial.
Authors: Jacobs, T. L., et al.
Journal: The New England Journal of Medicine
Abstract: This pragmatic trial equipped veterans with a mobile app to track symptoms and titrate personalized THC:CBD:CBG ratios. Results showed that tailored cannabinoid regimens led to a clinically significant (>3-point) reduction in composite pain and anxiety scores, outperforming fixed-dose formulations and highlighting the future of personalized plant-based medicine.
1. What Research Exists Comparing the Health Impacts of Hemp/THC-Infused Beverages vs. Alcoholic Beverages?
Response: Hemp/THC-infused beverages offer a promising alternative to alcohol, potentially reducing harm with benefits like pain relief and relaxation for adults. Today, many people are well aware of the effects of alcohol and seek cannabis as a alternative. Some of them, have had a personal negative experience with alcohol and are in search of an alternative. Studies show cannabis users often cut alcohol consumption, suggesting a safer social option. However, research is limited due to the novelty of THC beverages. Alcohol’s risks—liver disease, cancer—are well-documented, while cannabis lacks fatal overdose potential. With genuine concern, we note long-term data on THC beverages is sparse, and overconsumption can cause discomfort. These products are for adults, not children, unless medically indicated. More studies are needed to compare long-term effects.
2. How Can Cannabis Affect a Developing Brain?
Response: For adults, low-THC hemp beverages can be a safer alternative to alcohol, with minimal cognitive impact when used responsibly. However, we approach adolescent use (up to age 25) with caution, as the developing brain is sensitive. Studies show heavy THC use in teens may impair memory and increase cannabis use disorder risk. Low-THC hemp products (<0.3%) are less concerning but not risk-free. Alcohol also harms young brains, causing similar deficits. With genuine concern, these products are for adults; in children, cannabis is only indicated for severe medical conditions like epilepsy under medical supervision.
References:
3. Are There Any Mental Health Implications?
Response: THC-infused beverages can offer adults relief from anxiety and stress, with studies showing benefits like improved sleep for 60% of PTSD patients. CBD in hemp drinks may further promote calm without intoxication. However, we advise caution: high THC doses can increase anxiety or, rarely, trigger psychosis in predisposed adults. Adolescents face higher risks of depression with regular use. Alcohol carries similar mental health risks, including addiction. With genuine concern, these products are for adults; pediatric use is limited to medical indications like severe epilepsy. Responsible use is essential to maximize benefits.
References:
4. Why Has Cannabis Not Been Widely Studied?
Response: Cannabis beverages, especially hemp-based ones, hold exciting potential as safer alternatives to alcohol for adults, with early studies showing benefits for pain and anxiety. However, we note with caution that research lags due to cannabis’s Schedule I status in the U.S., which restricts funding and access to standardized products. The 2018 Farm Bill eased hemp research, but THC studies remain limited. Alcohol research, by contrast, has decades of support. Variability in cannabis formulations complicates trials. These products are for adults; pediatric use is restricted to medical needs. Policy changes are needed to expand research.
References:
5. Will We Have More Research in the Future?
Response: The growing popularity of THC-infused beverages, projected to reach a $2 billion market by 2030, is driving exciting research into their benefits for adults, such as reduced alcohol reliance. With caution, we note that federal restrictions and dosing variability slow progress. Ongoing trials, like NIDA’s and the ABCD Study, are exploring long-term effects. Future studies will likely clarify THC beverages’ safety versus alcohol. These products are for adults; pediatric use is limited to medical indications like epilepsy. With continued legalization, we expect robust research advancements.
References:
6. What Should One Know About Dosing/Servings (Pros + Cons)?
Response: THC-infused beverages offer adults a controlled, enjoyable alternative to alcohol, with precise dosing (2–10 mg THC) and faster onset (15–30 minutes) than edibles. Low-THC hemp drinks are widely accessible. With caution, overconsumption risks discomfort like anxiety, as effects can take 1–2 hours to peak; a 2024 study found 31% of hemp beverages had higher-than-labeled THC. Tolerance may develop, requiring higher doses. Alcohol’s dosing is better understood but carries hangover risks. These products are for adults; pediatric use is only for medical conditions like epilepsy. Start with 1–2 mg and wait patiently.
References: